Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials

Obesity Pillars · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles